Metagenomi Therapeutics (MGX) Cash & Equivalents (2023 - 2026)

Metagenomi Therapeutics (MGX) has reported Cash & Equivalents for 4 consecutive years, with $25.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents fell 13.32% year-over-year to $25.3 million; the TTM figure through Mar 2026 stood at $25.3 million (down 13.32% YoY), while the FY2025 annual figure was $41.7 million, up 52.35% from the prior year.
• Cash & Equivalents retreated to $25.3 million in Q1 2026 per MGX's latest filing, from $41.7 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $140.6 million in Q4 2023 and bottomed at $25.1 million in Q3 2024.
• Historically, Cash & Equivalents has averaged $58.6 million across 4 years, with a median of $41.7 million in 2025.
• Annual changes were most pronounced in 2024 — Cash & Equivalents slumped 80.52% — and 2025, when it jumped 52.35%.
• Metagenomi Therapeutics' Cash & Equivalents stood at $140.6 million in 2023, then plunged by 80.52% to $27.4 million in 2024, then surged by 52.35% to $41.7 million in 2025, then tumbled by 39.35% to $25.3 million in 2026.
• Business Quant data shows MGX's Cash & Equivalents at $25.3 million in Q1 2026, $41.7 million in Q4 2025, and $32.8 million in Q3 2025.